Vesicare · DIN 02277271 · 10 mg · tablet
Limited Use, Reason for Use code 290 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 290 required
Write on scriptReason for Use code 290 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vesicare · DIN 02277271
Manufacturer: Astellas Pharma Canada Inc.; listing date 2011-12-15
Health Canada: Marketed since 2006-06-23 · brand VESICARE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 10 MG · company Astellas pharma canada inc · schedule Prescription
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02277271)
Source record
DIN 02277271: Vesicare
Raw flags: sec12=Y, sec3=Y
Item: 920000639; group id 963; item number 2286; lccId 00218; manufacturer id ASE
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6892; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02277271
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76293
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439352 · $0.3041
Act Solifenacin · DIN 02422247 · $0.3041
Apo-Solifenacin · DIN 02423383 · $0.3041
Auro-Solifenacin · DIN 02446383 · $0.3041
Jamp Solifenacin Succinate · DIN 02428938 · $0.3041
Jamp-Solifenacin · DIN 02424347 · $0.3041
M-Solifenacin Succinate · DIN 02529718 · $0.3041
PMS-Solifenacin · DIN 02417731 · $0.3041
PRZ-Solifenacin · DIN 02493047 · $0.3041
Ran-Solifenacin · DIN 02437996 · $0.3041
Sandoz Solifenacin · DIN 02399040 · $0.3041
Solifenacin · DIN 02458268 · $0.3041
Solifenacin Succinate Tablets · DIN 02448343 · $0.3041
Teva-Solifenacin · DIN 02397919 · $0.3041
Shortage status: not checked (no credentials)